Home » Newsletters » BioWorld

BioWorld

July 5, 1994

View Archived Issues

PENEDERM OFFERS 1.7M SHARES HELD BY ORIGINAL INVESTORS

CORRECTIONS

PHARMA PATCH MAKES TAKEOVER BID FOR CANGENE

MEDIMMUNE FILES IND FOR LYME DISEASE VACCINE

GENETICS INSTITUTE'S EPO CLAIM UPHELD IN EUROPE

CYTRX BEGINS ENROLLING FOR WOUND HEALING STUDY

HOUGHTEN BEGINS PHASE I FOR INFLAMMATION, PAIN COMPOUND

HUMAN GENOME CENSUS BEFORE COUNTING GENES, ASK: WHAT COUNTS AS A GENE?

BIO PLANS LOBBYING ASSAULT ON CAPITOL HILL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...